Drug Sales Trends for HYDROCODONE

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for HYDROCODONE

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
HYDROCODONE			2022
HYDROCODONE			2021
HYDROCODONE			2020
HYDROCODONE			2019
HYDROCODONE			2018

Market Analysis and Sales Projections for Hydrocodone

Last updated: February 24, 2026

Hydrocodone is an opioid analgesic primarily used for pain relief and cough suppression. Its market size, regulatory landscape, and sales potential are influenced by public health concerns, regulatory changes, and emerging alternatives.

Market Overview

Hydrocodone ranks among the most prescribed opioids in the United States. In 2021, the drug generated approximately $4.2 billion in sales in the U.S., accounting for roughly 25% of the prescription opioid market. The North American market dominates globally, owing to high prescription rates and the prevalence of chronic pain conditions.

Regulatory Environment

In 2014, the U.S. Drug Enforcement Administration (DEA) reclassified hydrocodone combination products from Schedule III to Schedule II. This change increased regulations concerning prescribing, dispensing, and refill procedures. The reclassification aimed to curb misuse but also impacted prescription volumes and sales.

Recent legislative developments include:

• The implementation of Prescription Drug Monitoring Programs (PDMPs) limiting prescriptions.
• State-level restrictions and increased scrutiny on opioid prescribing.
• Set policies encouraging alternative pain management methods.

These regulations have tempered growth but haven't eliminated demand due to the ongoing need for effective pain management.

Market Segments

Prescription Segment

• Nearly 60% of hydrocodone sales derive from outpatient prescriptions.
• Key prescribers include pain clinics, hospitals, and primary care providers.

Generic vs. Branded

• Generic formulations constitute over 90% of sales, driven by lower costs and prescription preferences.
• Branded products account for less than 10%, primarily in specific formulations or combination products.

Formulation Types

• Immediate-release tablets dominate sales, with limited extended-release formulations approved.
• Combination products with acetaminophen or other agents account for most sales.

Competition

Hydrocodone faces competition from:

• Other opioids like oxycodone, morphine, and fentanyl.
• Non-opioid analgesics (NSAIDs, acetaminophen).
• Non-pharmacologic therapies (physical therapy, nerve blocks).

Market share concentration remains high among a few manufacturers, including Purdue Pharma, Alvogen, and Teva Pharmaceuticals.

Sales Projections

Short-term Outlook (Next 2 Years)

• Sales growth is modest, around 2-3% annually, driven by steady demand but constricted by regulatory measures.
• The trend toward alternative therapies may reduce prescription volumes slightly.

Mid-term Outlook (3-5 Years)

• Projected compound annual growth rate (CAGR) of 1-2% depending on policy shifts.
• Market saturation limits significant growth, especially as non-opioid therapies gain regulatory favor and insurance coverage improves for alternatives.

Long-term Outlook (Beyond 5 Years)

• Decline expected, around 1% annually, as the opioid epidemic prompts further restrictions.
• Development of abuse-deterrent formulations and new analgesic classes may decrease overall reliance on hydrocodone.

Potential Growth Drivers

• Expansion in emerging markets with rising healthcare infrastructure.
• New formulations with abuse-deterrent features.
• Increasing prevalence of chronic pain, particularly from aging populations.

Risks to Projections

• Stringent regulation and legislative bans.
• Legal challenges stemming from opioid litigation.
• Societal shifts favoring non-opioid pain management.

Key Data Summary

Aspect	Details
2021 U.S. Sales	$4.2 billion
Predominant Form	Generic immediate-release tablets
Market Share	25% of prescription opioids
Growth Rate (2022-2024)	2-3% annually
Long-term Decline	~1% annually beyond 2024

Key Takeaways

• Hydrocodone remains a major revenue contributor within pain management but faces declining growth prospects.
• Regulatory changes heavily influence prescribing habits and market size.
• Competition from non-opioid therapies and abuse-deterrent formulations poses long-term threats.
• Expected modest growth in emerging markets may offer new revenue streams.

FAQs

1. How will regulatory changes impact future hydrocodone sales?
Stricter prescribing rules and increased monitoring are expected to reduce sales growth. Universities and health agencies favor non-opioid alternatives, further constricting demand.

2. Are new formulations likely to boost sales?
Yes, formulations with abuse-deterrent properties could sustain or increase demand among prescribers and patients concerned about misuse.

3. Could legal actions influence sales?
Yes, ongoing opioid litigation may affect production or marketing practices, potentially leading to restrictions or increased liabilities.

4. What is the potential for growth in markets outside the U.S.?
Emerging markets with growing healthcare access present opportunities, but regulatory frameworks are less mature, which could create barriers.

5. How does competition from alternative therapies affect the market?
Alternative therapies, including non-opioid medications and non-pharmacologic treatments, could reduce reliance on hydrocodone over time.

References

1. IMS Health. (2022). U.S. Prescription Opioid Market Data.
2. DEA. (2014). Notice of Reclassification.
3. CDC. (2021). Opioid Prescribing and Monitoring Report.
4. Statista. (2022). Hydrocodone Sales Data.
5. MarketWatch. (2023). Pain Management Drugs Market Outlook.

[1] U.S. Food and Drug Administration. (2022). Hydrocodone products: regulatory status and market trends.